Medytox Inc. – Trademark Portfolio
Entity Type: 99
Medytox Inc. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 5 trademarks are registered and 3 are pending. Notable registered marks include NEWLUX, CORETOX, LUVANTAS, NEURAMIS, and NEURONOX.
78, Gangni 1-gil, Ochang-eup,
Cheongwon-gu, Cheongju-si Chungcheongbuk-do
Showing of trademarks Trademarks
Trademark Classifications
Medytox Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits
Frequently Asked Questions
How many trademarks does Medytox Inc. have?
Medytox Inc. has 18 U.S. trademarks filed with the USPTO. Of these, 5 registered, 3 pending, 6 abandoned, 1 cancelled.
What trademark classes does Medytox Inc. file in?
Medytox Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 3 (Cosmetics & Cleaning), Class 29 (Meats & Processed Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Medytox Inc.'s most well-known trademarks?
Medytox Inc.'s registered trademark portfolio includes well-known marks such as NEWLUX, CORETOX, LUVANTAS, NEURAMIS, and NEURONOX. These are among 5 currently registered trademarks in the portfolio.
What is Medytox Inc.'s trademark registration success rate?
Medytox Inc. has a 42% trademark registration rate, with 5 out of 12 resolved applications resulting in successful registration. Currently, 3 applications are pending review.